主页 > 医学新闻 >
【medical-news】癌基因蛋白单克隆抗体改善乳癌患
Main Category: Breast Cancer News
Article Date: 06 Jan 2007 - 10:00 PST
Giving women with a certain type of breast cancer Herceptin for one year following standard chemotherapy may improve their survival, according to an Article in this week’s issue of The Lancet.
Around 15 - 25% of women with early breast cancer have a type called HER2-receptor positive disease. Herceptin has been shown to reduce the risk of disease recurrence in women with HER2-positive early breast cancer. In the Herceptin Adjuvant (HERA) study, Ian Smith (Royal Marsden Hospital, London, UK) and colleagues assessed the effect of the drug on overall survival after two years follow-up.
On the trial 1703 women were randomised to receive Herceptin for one year after surgery and chemotherapy and 1698 women were assigned to the control group (observation only). They found that more deaths occurred in the observation group than in the drug group (90 vs59), which corresponds to a survival benefit of 2·7% after 3 years. There were more serious side effects in the Herceptin group than in the observation group.
Dr Smith concludes: "Our results indicate that trastuzumab [Herceptin] shows a significant overall survival benefit in early breast cancer over observation alone after chemotherapy. . . The survival benefit that has emerged over such a short period emphasises the potential of this approach and underlines the importance of developing further specific targeted therapies in breast and other cancers."
http://www.lancet.com
http://www.medicalnewstoday.com/medicalnews.php?newsid=60099 本人认领该文件,48小时后若未回复,请其他战友自由认领 Herceptin Improves Early Survival For Women With Breast Cancer
癌基因蛋白单克隆抗体改善乳癌患者的早期存活率
Giving women with a certain type of breast cancer Herceptin for one year following standard chemotherapy may improve their survival, according to an Article in this week’s issue of The Lancet.
据本周的《柳叶刀》杂志中一篇文章报告，患有特定类型乳腺癌的患者应用赫赛汀进行一年标准化疗，可改善其生存率。
Around 15 - 25% of women with early breast cancer have a type called HER2-receptor positive disease. Herceptin has been shown to reduce the risk of disease recurrence in women with HER2-positive early breast cancer. In the Herceptin Adjuvant (HERA) study, Ian Smith (Royal Marsden Hospital, London, UK) and colleagues assessed the effect of the drug on overall survival after two years follow-up.
大约15-25%的早期乳腺癌患者所患类型为HER2-受体阳性乳腺癌。赫赛汀已被证明可降低HER2-受体阳性早期乳腺癌患者的复发风险。在赫赛汀辅助治疗研究(HERA)中，Ian Smith（英国伦敦皇家马斯登医院）及其同事们在两年的随访后评价了该药对总生存率的影响。
On the trial 1703 women were randomised to receive Herceptin for one year after surgery and chemotherapy and 1698 women were assigned to the control group (observation only). They found that more deaths occurred in the observation group than in the drug group (90 vs59), which corresponds to a survival benefit of 2•7% after 3 years. There were more serious side effects in the Herceptin group than in the observation group.
参与该试验的1703名患者被随机分配并在手术和化疗后1年内服用赫赛汀，另外1698名患者作为对照组（只观察）。他们发现观察组比用药组死亡数多（90比59），相应的3年生存效益为2.7%。但赫赛汀治疗组严重副反应比观察组多。
Dr Smith concludes: "Our results indicate that trastuzumab [Herceptin] shows a significant overall survival benefit in early breast cancer over observation alone after chemotherapy. . . The survival benefit that has emerged over such a short period emphasises the potential of this approach and underlines the importance of developing further specific targeted therapies in breast and other cancers."
Smith博士说：“我们的研究结果表明与单纯化疗后观察比较，应用群司珠单抗[赫赛汀]可使早期乳腺癌患者总生存率明显提高。在如此短期内就表现出良好的生存效益使得该疗法颇具应用潜力，同时也强调了进一步开发乳腺癌和其他癌症特异靶向疗法的重要性。”
修改编译：
据本周《柳叶刀》杂志一篇文章报告，HER2-受体阳性乳腺癌患者应用赫赛汀（群司珠单抗）进行一年标准化疗，可改善其生存率。
在所有早期乳腺癌患者中，大约15-25%所患类型为HER2-受体阳性乳腺癌。赫赛汀早已被证明可降低HER2-受体阳性早期乳腺癌患者的复发风险。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-30 17:33
医学,生命科学网